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classification of synapses into asymmetric and symmetric types (Gray 1959) . Asymmetric synapses, also called Gray's type I synapses, are usually excitatory, use glutamate as a neurotransmitter and are formed on dendritic spines. They feature a prominent electron-dense thickening at the cytoplasmic surface of the post-synaptic membrane called a postsynaptic density (PSD). Intensive proteomic and molecular cloning analyses have identified the molecular components of excitatory PSDs, which consist of glutamate receptors, cell adhesion molecules, scaffolding and adaptor proteins, cytoskeletal proteins, and signaling molecules including regulators of small GTPases, protein kinases and phosphatases (Scannevin and Huganir 2000) .
By contrast, symmetric synapses, also called Gray's type II synapses, are usually inhibitory, use either GABA or glycine as neurotransmitters and are mainly formed on dendritic shafts and cell bodies. The PSD at inhibitory synapses is less electron-dense, having a similar size to the active zone on the pre-synaptic membrane. Our understanding of the molecular organization of inhibitory synapses lags behind that of excitatory PSDs, in part because of the difficulty of purification of inhibitory PSDs. Several components such as gephyrin and dystrophin-associated glycoprotein complex (DGC) are found to localize selectively at post-synaptic specializations of inhibitory synapses and are proposed to be essential for the formation and maintenance of inhibitory synapses. Gephyrin is a 93-kDa peripheral membrane protein that was originally co-purified with glycine receptors (Pfeiffer et al. 1982) . Several lines of evidence indicate that gephyrin is essential for the post-synaptic clustering of glycine receptors (Kirsch et al. 1993; Feng et al. 1998) and a2-and c2-subunit containing GABA A receptors (GABA A Rs) (Essrich et al. 1998) . Gephyrin functions as synaptic scaffold and regulator of receptor trafficking by interacting with various membrane, signaling, cytoskeletal, and trafficking proteins (Kneussel and Betz 2000; Fritschy et al. 2008) . Among gephyrin-interacting proteins, collybistin, a guanine nucleotide exchange factor (GEF), was originally considered to govern synaptic gephyrin localization, because collybistin splice variants lacking a src homology 3 domain can recruit gephyrin from intracellular aggregates to submembrane clusters in heterologous transfection systems (Kins et al. 2000; Harvey et al. 2004) . However, most isoforms in vivo harbor an Src homology 3 domain, which mediates activation of collybistin-mediated gephyrin clustering by neuroligin 2 (Poulopoulos et al. 2009) . Curiously, studies with collybistin-deficient mice have revealed that collybistin is only essential for gephyrindependent clustering of specific subsets of GABA A Rs in the hippocampus and amygdala (Papadopoulos et al. 2007) , suggesting that other clustering mechanisms must operate at inhibitory synapses. On the other hand, the DGC is a large multiprotein complex that links the extracellular matrix to the cytoskeleton. Several components of the DGC, including a-and b-dystroglycan, dystrophin, and b-dystrobrevin were shown to selectively localize to inhibitory synapses on neuronal somata and dendrites (Knuesel et al. 1999; Brunig et al. 2002; Levi et al. 2002; Grady et al. 2006) . A study with dystrophin mutant mdx mice also demonstrated that a lack of dystrophin reduced the clustering of GABA A R a1 and a2 subunits in the hippocampus and cerebellum (Knuesel et al. 1999) , suggesting that gephyrin-independent mechanisms also regulate the clustering of GABA A R a1 and a2 subunits.
SynArfGEF(Po), named as a potential synaptic guanine nucleotide exchange factor (GEF) for the ADP ribosylation factor (Arf) family of small GTPases, was originally identified by screening for mRNA species associated with the PSD fraction (Inaba et al. 2004) . SynArfGEF(Po) contains an N-terminal coiled-coil motif, a calmodulinbinding IQ-like motif, central Sec7 domain and pleckstrin homology domain and a C-terminal type I PSD-95/Disc large/Zonula occludens 1 (PDZ)-binding motif (Inaba et al. 2004) . All Arf-GEFs contain a Sec7 domain, an approximately 200-amino acid protein module that is critical for the catalysis of GDP-GTP exchange on Arf GTPases. SynArfGEF(Po) belongs to the brefeldin A-resistant Arf-GEF (BRAG)/IQSEC subfamily of Arf-GEFs based on the phylogenic classification of Sec7 domains (Cox et al. 2004) . The Arf family comprises six structurally related members (Arf1-6) that play an essential role in membrane trafficking and cytoskeletal rearrangements (D'Souza-Schorey and Chavrier 2006). Among six Arf members, Arf6 is the most divergent in terms of structure, localizes at plasma membrane and endosomes, and regulates recycling of the plasma membrane and peripheral actin cytoskeleton. In neurons, Arf6 is implicated in the formation and maintenance of dendritic spines (Choi et al. 2006) , the branching of axons and dendrites (Hernandez-Deviez et al. 2002 , 2004 , exocytosis and endocytosis of synaptic vesicles (Vitale et al. 2002; Krauss et al. 2003) and receptor internalization (Delaney et al. 2002; Krauss et al. 2003; Claing 2004; Houndolo et al. 2005) . SynArfGEF(Po) mRNA is expressed widely in the rat brain and localized at dendrites as well as cell bodies, suggesting activity-dependent local translation (Inaba et al. 2004) . Although synArfGEF(Po) protein shows a punctate appearance in cell bodies and dendrites of cultured neurons, its subcellular localization has not been characterized in detail to date.
To obtain a better understanding of the functional significance of synArfGEF(Po), we first demonstrated its ability to activate Arf6 and therefore renamed it synArfGEF. Next, we examined the immunohistochemical localization of synArfGEF in the mouse brain. Intriguingly, synArfGEF exhibited somatodendritic localization with a high selectivity for post-synaptic specializations of inhibitory synapses. We further demonstrated the ability of synArfGEF to interact with utrophin/dystrophin and synaptic scaffolding molecule (S-SCAM) by yeast two-hybrid and pull down assays. These findings indicate that synArfGEF is a novel signaling component at inhibitory post-synaptic sites.
Materials and methods
All animal protocols were approved by the Animal Experimentation and Ethics Committee of the Kitasato University School of Medicine and followed the guidelines of the National Institutes of Health.
Vectors
Mammalian expression vectors for synArfGEF (pCAGGS-FLAGsynArfGEF) and GEP100/BRAG2 (pCAGGS-FLAG-GEP100) were made by amplifying the coding regions of rat synArfGEF and mouse GEP100 using PCR with primers containing EcoRI restriction sites (underlined) as follows: sense, 5¢-GAATTCATGGAGAGCCTGC TGGAGAACCCGG-3¢ and antisense, 5¢-GAATTCCTACACCAGG CTCCTGGAGCCACTG-3¢ for synArfGEF; sense, 5¢-GAATTCAT GCTAGAACGCAAGTATGGGGGAC-3¢ and antisense, 5¢-GAAT TCTTAGGAGCACAGCACTGGAGGCTG-3¢ for GEP100. After subcloning into pGEM-T Easy (Promega, Madison, WI, USA), the cDNA fragments were digested with EcoRI and ligated into the same restriction site of pCAGGS-FLAG (Niwa et al. 1991; Sakagami et al. 2005) . A mammalian expression vector for IQ-ArfGEF/BRAG1, pCAGGS-FLAG-IQ-ArfGEF/BRAG1, was described previously (Sakagami et al. 2008) . The expression vectors for S-SCAM [pCIneoMyc S-SCAM (1-1277), (1-301), (295-578), (423-578)] were described previously (Sumita et al. 2007 ). The expression vectors for C-terminally hemagglutinin (HA) epitope-tagged Arf1 and Arf6 in pcDNA3 (Hosaka et al. 1996) were kindly provided by Dr Kazuhisa Nakayama (Kyoto University). The expression vector for C-terminally FLAG-tagged Arf6(Q67L) mutant in pCAGGS-neo (Tanabe et al. 2005) was kindly provided by Dr Masanobu Satake (Tohoku University).
For Arf pull down assays, the bacterial expression vector containing the GAT domain of Golgi-localizing, c-adaptin ear homology domain, Arf-binding protein 1 (GGA1) (Shinotsuka et al. 2002) was kindly provided by Dr Kazuhisa Nakayama (Kyoto University).
For pMAL-SXN, a bacterial expression vector that has the same reading frame for the SalI cloning site as that of pGEX4T-2 (GE Healthcare, Piscataway, NJ, USA), oligonucleotides containing SalI, XhoI and NotI sites (5¢-AATTGTCGACTCGAGCGGCCGCTGCA-3¢ and 5¢-GCGGCCGCTCGAGTCGAC-3¢) were annealed and ligated into the EcoRI and PstI sites of pMAL-c2 (New England Biolabs, Beverly, MA, USA). To prepare antigens for immunization and affinity purification, the N-terminal region (amino acids 1-293) of rat synArfGEF, the entire coding region of mouse gephyrin, the region between PDZ1 and PDZ2 domain of rat S-SCAM (amino acids 510-570), the region containing 13th and 14th spectrin repeats of mouse utrophin (amino acids 1761-2101) were amplified by PCR with the following primers containing a SalI site (underlined) in sense primers and a stop codon (small letters) in antisense primers: 5¢-GTCGACCATGGAGAGCCTGCTGGAGAACCCGG-3¢ and 5¢-ctaTAGGTCAAGGGAGAGTTCGTACTC-3¢ for synArfGEF; GT CGACCATGGCGACCGAGGGAATGATCCTCAC-3¢ and tcaTAG CCGTCCAATGACCATGACATC-3¢ for gephyrin; 5¢-GTCGAC CTGTCGTGGCTACCCTTTGCCCTTTG and 5¢ctaGTGCAA AGAATGAGGTGGCCGGTCTG-3¢ for S-SCAM; 5¢-GTCGAC GACCCTGCTGGAACTGTTCAAGCTGC-3¢ and 5¢-ttaCGTTAA CCAGCAGGTGACCTCATCTAGCC-3¢ for utrophin. After subcloning into pGEM-T Easy, the cDNA fragments were digested with SalI and NotI and ligated into the same restriction sites of pGEX4T-2 and pMAL-SXN.
For in vitro binding assays, the C-terminal region of rat synArfGEF (amino acids 1122-1194) was amplified by PCR with primers containing a SalI site (underlined) (5¢-GTCGACCAT GGAGCCCCTGCTGAGCCAGGCTC-3¢ and 5¢-CTACACCAG GCTCCTGGAGCCACTG-3¢). After subcloning into pGEM-T Easy, the cDNA fragment digested with SalI and NotI was ligated into the same restriction sites of pGEX4T-2. The C-terminal regions of utrophin corresponding to amino acids 2961-3429, 2691-3058, and 2691-2843 and dystrophin corresponding to amino acids 2937-3685 were amplified by PCR using the primer combinations listed in Table S1 and ligated into pGEM-T Easy. The inserts were digested with SalI and NotI and ligated into the same sites of pGEX4T-2.
To construct bait vectors for yeast two-hybrid assays, the C-terminal regions of synArfGEF shown in Fig. 7b were amplified by PCR with primer combinations listed in Table S1 and rat synArfGEF cDNA as a template. After ligation into pGEM-T Easy, the inserts were ligated into SalI and NotI sites of pDBLeu (Invitrogen Corp., Carlsbad, CA, USA) downstream and in frame with the GAL4 DNA binding domain. For pDBLeu-synArfGEF(PPPPY fi PPAPA), mutations were introduced in a PY motif at the C-terminus of synArfGEF using the PrimeSTAR mutation basal kit (Takara, Tokyo, Japan) with pDBLeu-synArfGEF(1122-1194) and mutagenesis oligonucleotides (sense, 5¢-CCCCAGCCCCAGCCAACCACCCTCACCAGTT-3¢; antisense, 5¢-GTGGTTGGCTGGGGCTGGGGGTGGGGGCAGTGG-3¢). To construct prey vectors encoding truncated mutants of utrophin and dystrophin as shown in Fig 6a, PCR was carried out with the primer combinations listed in Table S1 . After ligation into pGEM-T Easy, the inserts digested with SalI and NotI were ligated into the same sites of pPC86. All inserts created in this study were confirmed by Sanger DNA sequencing.
Arf Pull down assay
The GEF activity of synArfGEF was examined by Arf pull down assays with GGA1 as described previously Sakagami et al. 2006) . COS-7 cells were transfected with pcDNA3-Arf1-HA or pcDNA3-Arf6-HA in the presence or absence of pCAGGS-FLAG-synArfGEF using Lipofectamine 2000 (Invitrogen). Cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM MgCl 2 , 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol and a cocktail of protease inhibitors (Complete Mini TM , Roche, Mannheim, Germany). After centrifugation, the supernatants were incubated with 40 lg of glutathione S-transferase (GST)-GGA1 fusion protein immobilized on glutathione-Sepharose 4B (GE Healthcare) for 1 h at 4°C. The precipitates and lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to Western blot analysis with anti-HA (Clontech Laboratories, Palo Alto, CA, USA) or anti-FLAG antibodies (M2, Sigma-Aldrich, Inc., St Louis, MO, USA). Immunoreactive bands were visualized using a chemiluminescent reagent (ECL-PLUS Western blotting detection kit, GE Healthcare) and X-ray films. ImageJ (NIH) was used to measure the densities of immunoreactive bands and statistical analysis was performed using Student's t-test.
Transferrin incorporation
HeLa cells were transfected with pcDNA3-Arf6(Q67L)-FLAG or pCAGGS-FLAG-synArfGEF plus pcDNA3-Arf6-HA using Lipofectamine 2000. One day after transfection, cells were serum-starved for 3 h and incubated with Alexa488-conjugated transferrin (25 lg/ mL) for 20 min at 37°C. The cells were then fixed with 4% paraformaldehyde and immunostained with anti-FLAG IgG. Fluorescent images and intensities were acquired using a confocal microscope (TCS SP2 AOBS, Leica Microsystems, Wetzlar, Germany). The fluorescent intensities of cytoplasmic transferrin in transfected cells were statistically compared with those in nontransfected cells observed in the same fields using Scheffe's test. Three independent experiments were performed.
Antibodies
The fusion proteins of GST and maltose-binding protein to synArfGEF, gephyrin, S-SCAM, or utrophin were expressed in Escherichia coli BL21 (DE3) (Stratagene) in the presence of 1 mM isopropyl b D-thiogalactopyranoside and purified with glutathioneSepharose 4B and amylose-resin (New England Biolabs), respectively. These GST fusion proteins were then used to immunize rabbits and guinea pigs. The antibodies were affinity-purified with CNBr-activated Sepharose (GE Healthcare) coupled with respective maltose-binding protein fusion proteins. The specificity of antibodies for gephyrin, S-SCAM, utrophin was characterized by Western blot analysis ( Figure S1 ).
Western blot analysis
Mouse brains and COS-7 cells transfected with pCAGGS-FLAGsynArfGEF, pCAGGS-FLAG-IQ-ArfGEF/BRAG1 or pCAGGS-FLAG-GEP100 were homogenized with a buffer containing 125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 1% sodium deoxycholate, 10% b-mercaptoethanol and a cocktail of protease inhibitors (Complete Mini TM , Roche) and boiled for 5 min. After centrifugation, the lysates were separated by SDS-PAGE and transferred onto polyvinyl difluoride membranes (PVDF-PLUS, Micron Separations Inc., Westborough, MA, USA). The membranes were incubated with antibodies against synArfGEF (0.5 lg/mL) or FLAG (M2, Sigma-Aldrich, 0.5 lg/mL) and subsequently with peroxidase-conjugated secondary antibodies. Immunoreactive bands were visualized using a chemiluminescent reagent (ECL-PLUS Western blotting detection kit, GE Healthcare).
Immunostaining
To confirm the specificity of antibodies, COS-7 cells were plated onto 35-mm dishes at the density of 2 · 10 5 per dish and transfected with pCAGGS-FLAG-synArfGEF, pCAGGS-FLAG-IQ-ArfGEF/ BRAG1 or pCAGGS-FLAG-GEP100 using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, cell were fixed with 4% paraformaldehyde and subjected to double immunostaining with antibodies against synArfGEF and FLAG epitope. Under deep anesthesia with diethyl ether, C57BL/6N male mice at postnatal 10-12 weeks transcardially fixed with 4% paraformaldehyde plus 0.2% picric acid in 0.1 M phosphate buffer (pH 7.4). Brains were further immersed with the same fixative overnight, cryoprotected in 30% sucrose, and sliced at a thickness of 30 lm with a cryostat. Hippocampal cultures were prepared from 18-dayold rat embryos at the plating density of 0.6 · 10 6 per 35-mm dish as described previously (Sakagami et al. 2005) . At 22 days in vitro, plates were fixed with 2% paraformaldehyde for 5 min. For immunoperoxidase staining, brain sections were solubilized in 0.3% Triton X-100 for 30 min, blocked with 5% normal goat serum for 30 min, and incubated with anti-synArfGEF IgG (1 lg/ mL) overnight. After washing extensively with phosphate-buffered saline, they were subsequently incubated with peroxidase-conjugated anti-rabbit IgG (Histofine Simple Stain MAX PO (R) kit, Nichirei, Tokyo, Japan) for 1 h at 23°C. Immunoreactions were visualized with 3,3¢-diaminobenzidine tetrahydrochloride chromogenic substrate (Liquid DAB and Substrate Chromogen System, K3468; DAKO, Tokyo, Japan). The pre-embedding silver-enhancement immunogold method was described previously (Sakagami et al. 2008) . Briefly, after incubation with the primary antibody, the sections were incubated with nanogold-conjugated anti-rabbit IgG (1 : 100, Nanoprobes Inc., Yaphank, NY, USA), washed with phosphate-buffered saline, and fixed with glutaraldehyde for 10 min. The gold labeling was intensified for 3-5 min under a safety red light using a HQ Silver Enhancement kit (Nanoprobe Inc.) according to the manufacturer's instructions. The sections were treated with 1% osmium tetroxide and 2% uranyl acetate, dehydrated with ethanol and embedded in epoxy resin. Ultrathin sections were examined with a JEM-1230 electron microscope (JEOL Ltd., Tokyo, Japan).
For immunofluorescent staining, samples were incubated with the combination of rabbit or guinea pig polyclonal anti-synArfGEF IgG with guinea pig anti-gephyrin IgG, guinea pig anti-PSD-95 IgG (Fukaya and Watanabe 2000) , rabbit anti-IQ-ArfGEF/BRAG1 (Sakagami et al. 2008) , rabbit GABA A R a1 subunit IgG (Alamone Labs, Jerusalem, Israel), anti rabbit anti-vesicular GABA transporter (VGAT) (Fukudome et al. 2004) , guinea pig anti-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate-type glutamate receptor GluA2 subunit IgG (Yamazaki et al. 2010) , guinea pig anti-S-SCAM IgG, mouse monoclonal anti-glycine receptor a1 subunit IgG (clone mAb4a, Synaptic Systems, Gottingen, Germany) or anti-dystrophin IgG (MANDRA-1, Sigma). Immunoreactions were visualized with the appropriate combination of the following secondary antibodies: Alexa488-conjugated anti-rabbit IgG, Alexa488-or Alexa594-conjugated anti-guinea pig IgG, and Alexa594-or Alexa647-conjugated anti-mouse IgG (Molecular Probes, Inc., Eugene, OR, USA). Nuclei were counter-stained with 4¢,6-diamidino-2-phenylindole dihydrochloride. Immunofluorescent images were taken with a confocal microscope (LSM 710, Carl Zeiss, Oberkochen, Germany) using ·20 and ·63 plan-apochromat objective lens. The brightness and contrast of the final images were adjusted using Photoshop CS4 software (Adobe Systems, San Jose, CA, USA). In control experiments, the primary antibody was pre-incubated with the antigen (10 lM) before immunostaining.
Yeast two-hybrid assay Yeast two-hybrid screening was performed as described previously (Sakagami et al. 2007 (Sakagami et al. , 2008 . Briefly, approximately 2 · 10 6 clones of a mouse brain cDNA library were screened using pDBLeu-synArfGEF(1122-1194), which encoded the fusion protein of C-terminal 73 amino acids of rat synArfGEF to the GAL4 DNAbinding domain, by the ability to grow on selective medium lacking histidine, leucine and tryptophan supplemented with 10 mM 3-aminotriazole. Positive colonies were further selected by the b-galactosidase assay and uracil prototrophy. Plasmids were subjected to the sequencing analysis. To verify the interaction, the yeast strain MaV203 was co-transformed with the indicated combination of bait pDBLeu and prey pPC86 vectors shown in Figs 6 and 7. The interactions were tested by the b-galactosidase assay and the ability to grow without histidine and uracil.
In vitro binding assay COS-7 cells were transiently transfected with various plasmid constructs encoding myc-tagged S-SCAM or FLAG-synArfGEF and lysed in the lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40 and a cocktail of protease inhibitors (Complete Mini TM , Roche). Lysates were incubated with 15 lg of GST, GST-synArfGEF 1122-1194, GST-utrophin 2691 -3429, 2691 -3058, 2691 -2843 , 2937 2937-3685, immobilized on glutathione-Sepharose 4B for 1 h at 4°C. Afterwards, the beads were washed five times with the lysis buffer containing 150 mM or 300 mM NaCl and the proteins were eluted with SDS sample buffer. The cell lysates and eluates were analyzed by Western blot analysis with anti-myc IgG or anti-FLAG IgG.
For pull down assays from brain extracts, mouse brains were homogenized with 10 volumes of the lysis buffer and centrifuged at 12 000 g for 15 min. The supernatant (1 mg) were pre-cleaned with glutathione-Sepharose 4B for 30 min and incubated with 20 lg of GST, GST-utrophin 2691-3429, or GST-dystrophin 2937-3685, which were immobilized on glutathione-Sepharose 4B, for 1 h at 4°C. The precipitates were washed with the lysis buffer containing 150 or 300 mM NaCl and subjected to Western blot analysis with rabbit anti-synArfGEF IgG.
Immunoprecipitation
Immunoprecipitation from brain lysates was performed as described previously (Sakagami et al. 2008) . Briefly, the mouse brain P2 fraction was solubilized with 1% sodium deoxycholate in 50 mM Tris-HCl (pH 9.0) and dialyzed against the binding buffer [0.1% Triton X-100, 50 mM Tris-HCl (pH 7.4)]. After pre-cleaning with Protein G-Sepharose 4B, the soluble supernatant (1 mg) was incubated with 5 lg of anti-synArfGEF IgG or normal rabbit IgG for 1 h at 4°C and with Protein G-sepharose 4B for another 1 h. The beads were washed five times with the binding buffer plus 150 mM NaCl. Proteins were eluted with SDS sample buffer, subjected to SDS-PAGE and immunoblotted with antibodies against S-SCAM (M2441, Sigma) or b-dystroglycan (clone 43DAG1/8D5, Novacastra Laboratories, Newcastle, UK).
Results

SynArfGEF activates Arf6
Two related proteins in the BRAG/IQSEC family of ArfGEFs, IQ-ArfGEF/BRAG1/IQSEC2 and GEP100/BRAG2/ IQSEC1 have previously been shown to activate Arf6 (Someya et al. 2001; Sakagami et al. 2008) . To examine whether synArfGEF/BRAG3/IQSEC3 activates Arf6, we performed Arf pull down assays with a GST-GGA1 fusion protein that is capable of binding GTP-bound Arfs of all classes. COS-7 cells were co-transfected with FLAGsynArfGEF and Arf1-HA or Arf6-HA. Immobilized GST-GGA1 pulled down 4.13-fold more GTP-Arf6-HA from the lysates of COS-7 cells expressing both Arf6-HA and FLAGsynArfGEF than Arf6-HA alone (p = 0.0092 by Student's t-test, Fig. 1a and b) . Co-transfection of Arf1-HA and FLAG-synArfGEF increased both total and GTP-bound Arf1 to a similar extent and did not change the ratio of GTP-Arf1 to total Arf1 ( Fig. 1a and b) . We further examined the ability of synArfGEF to activate Arf6 in vivo using a transferrin incorporation assay. Arf6 has been shown to regulate the endocytosis of transferrin receptor (D'SouzaSchorey et al. 1995) . If synArfGEF activates Arf6 in vivo, transferrin uptake would be affected by over-expressing synArfGEF. We therefore examined the incorporation of transferrin in HeLa cells transfected with FLAG-synArfGEF and Arf6-HA. In non-transfected cells, transferrin accumulated in the perinuclear region (Fig 1c) . By contrast, the incorporation of transferrin was reduced by 48.7% in cells transfected with FLAG-synArfGEF and Arf6-HA compared to non-transfected cells ( Fig. 1c and d) . This reduction was comparable with the reduction (31.9%) observed for cells transfected with the GTP hydrolysis-defective Arf6 mutant, Arf6(Q67L). Taken together, these findings suggest that synArfGEF activates Arf6 in vivo.
Preferential localization of synArfGEF at inhibitory synapses We have previously shown that synArfGEF mRNA is expressed preferentially in the olfactory bulb, cerebral cortex, hippocampus, brainstem nuclei and cerebellar Purkinje cells of the adult rat brain (Inaba et al. 2004) . In this study, we produced novel anti-synArfGEF antibodies for use in immunohistochemistry. Western blot analysis using the lysates of COS-7 cells transfected with FLAG-tagged BRAG family members showed that both antibodies raised in rabbit and guinea pig detected FLAG-synArfGEF, while they did not cross-react with other BRAG members, FLAG-IQArfGEF/BRAG1 or GEP100 (Fig. 2) . In the mouse brain lysate, the antibodies gave two immunoreactive bands of 160 and 130 kDa (Fig. 2) , suggesting the existence of two alternatively spliced isoforms as is the case for the other BRAG/IQSEC family members (Dunphy et al. 2006; Shoubridge et al. 2010) . Notably, the electrophoretic mobility of the 160 kDa band was consistent with that of recombinant FLAG-synArfGEF detected using an anti-FLAG antibody (Fig. 2) . Further to confirm the specificity, COS-7 cells were transfected with FLAG-tagged BRAG members and subjected to immunostaining. Again, the antibodies specifically detected COS-7 cells transfected with FLAG-synArfGEF without any immunolabeling in non-transfected cells or cells transfected with FLAG-IQ-ArfGEF/BRAG1 or GEP100 ( Figure S2 ). Immunoperoxidase staining of mouse brain sections with rabbit anti-synArfGEF IgG yielded intense labeling in the olfactory bulb, cerebral cortex, hippocampal formation, reticular thalamic nucleus, superior and inferior colliculi, cerebellar cortex and various brainstem nuclei (Fig. 3a) . This immunolabeling pattern was compatible with the expression pattern of synArfGEF mRNA in the rat brain described previously (Inaba et al. 2004) . In control experiments, the primary antibody pre-absorbed with the antigen did not show any immunolabeling (Fig. 3b) . In addition, both rabbit and guinea pig antibodies gave an identical labeling pattern (data not shown). Taken together, all these Fig. 2 Characterization of anti-synArfGEF antibodies by Western blot analysis. Lysates from mouse brain and COS-7 cells expressing FLAG-tagged synArfGEF, IQ-ArfGEF/BRAG1, or GEP100 were subjected to Western blot analysis with rabbit and guinea pig polyclonal antibodies against synArfGEF or anti-FLAG IgG.
findings suggest the immunolabeling observed with these antibodies is specific for synArfGEF. In the hippocampus, synArfGEF immunoreactivity was widely distributed, with the highest level observed in the CA3 region (Fig. 3c) . SynArfGEF labeling was observed diffusely in both neuronal somata and dendrites, but not in nuclei, of pyramidal cells. In addition to this diffuse cytoplasmic labeling, tiny puncta (< 1 lm in diameter) were distributed on the surface of the somata and dendrites (Fig. 3d) , consistent with synaptic localization. To examine whether synArfGEF is associated with excitatory or inhibitory synapses, double immunofluorescence staining was performed with antibodies against synArfGEF and PSD-95, gephyrin or IQ-ArfGEF/BRAG1 (Fig. 3e-m) . Extensive colocalization was observed between synArfGEF and gephyrin along somata and dendritic shafts (Fig. 3e-g ), whereas synArfGEF puncta were rarely co-localized with PSD-95 or IQ-ArfGEF/BRAG1 (Fig. 3h-m) .
In the olfactory bulb, synArfGEF immunoreactivity was distributed in the mitral cell, external plexiform, and glomerular layers (Fig. 3n) . In mitral cells, somata and dendrites were heavily immunolabeled. Along their dendritic shafts in the external plexiform layer, synArfGEF labeling was distributed as puncta largely co-localized with gephyrin ( Fig. 3o-q) .
In the neocortex, synArfGEF immunoreactivity was distributed throughout the cortical layers. Pyramidal neurons in the layer V were intensely immunolabeled in their somatodendritic compartments without nuclear staining (s) and gephyrin (t). Nuclei were counter-stained with 4¢,6-diamidino-2-phenylindole dihydrochloride (DAPI) (blue) in panles d, n, and r. CA1-3, subfield CA1-3 of Ammon's horn; Cb, cerebellar cortex; CP, caudate putamen; Cx, cerebral cortex; DG, dentate gyrus; Gr, dentate granule cell layer; Hi, hippocampus; Md, midbrain; Mi, mitral cell layer; MO, medulla oblongata; Mo, molecular layer, OB, olfactory bulb; SL, stratum lucidum; SLM, stratum lacunosummoleculare; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; Th, thalamus. Scale bars, 1 mm (a); 200 lm (c); 10 lm (d, n, R); 5 lm (g, j, m, q, u). (Fig. 3r) . At high magnification, synArfGEF was found in fine puncta along the somata and dendrites, which were largely co-localized with gephyrin ( Fig. 3s-u) .
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In the cerebellar cortex, synArfGEF immunoreactivity was observed in the somata and dendritic shafts of Purkinje cells, and the somata of basket cells and stellate cells in the molecular layer, and the somata of Golgi cells in the granular layer (Fig. 4a) . However, the somata of granule cells were devoid of immunolabeling for synArfGEF. At high magnification, tiny immunoreactive puncta were found to be distributed along Purkinje cell dendrites and co-localized well with gephyrin ( Fig. 4b-d) and GABA A R a1 subunit (Fig. 4e-g ) without overlapping with a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor GluA2 subunit (Fig. 4h-j) .
In the spinal cord, synArfGEF immunoreactivity was distributed in the gray matter. In particular, the somata and dendrites of ventral motoneurons were heavily immunolabeled (Fig. 4k) . The immunoreactive puncta along the somata and dendritic shafts were largely co-localized with both glycine receptors and gephyrin (Fig. 4k-n) . Immunoreactive puncta were also closely apposed to VGAT labeling, forming merged color at the interface ( Fig. 4o-q) . These confocal microscopic results suggest that synArfGEF is preferentially distributed at inhibitory synapses throughout the central nervous system.
To determine the precise synaptic localization, we performed pre-embedding immunogold electron microscopy in the external plexiform layer of the olfactory bulb (Fig. 5a) , the molecular layer of the cerebellar cortex (Fig. 5b) , and spinal motoneurons (Fig. 5c) . Immunogold particles for synArfGEF accumulated on or beneath the post-synaptic membrane of symmetric synapses formed on dendritic shafts and cell bodies. By contrast, no significant immunogold particles were observed at asymmetric synapses on olfactory mitral cells (Fig. 5a ), cerebellar Purkinje cells (Fig. 5b) , or spinal motoneurons (Fig. 5c ). These findings confirm that synArfGEF localizes exclusively at post-synaptic specializations of inhibitory synapses.
Interaction of synArfGEF with utrophin/dystrophin
To identify interacting proteins with synArfGEF, we performed yeast two-hybrid screening of a mouse brain cDNA library, using the C-terminal 73 amino acids of synArfGEF as bait. We isolated two independent cDNA clones (#5 and #57) encoding utrophin, a large cytoskeletal protein with high structural similarity to dystrophin (Fig. 6a) . Both clones encoded an overlapping C-terminal region (amino acids 2698-3429) containing a partial 20th spectrin repeat, the WW and Zn 2+ finger motifs, and two coiled-coil domains. As dystrophin was shown to localize at inhibitory synapses and to regulate the clustering of selected GABA A R subtypes (Knuesel et al. 1999) , we further examined whether the corresponding C-terminal region of dystrophin (amino acids 2937-3685) could interact with the C-terminus of synArfGEF. Indeed, yeast expressing dystrophin 2937-3685 and synArfGEF 1122-1194 exhibited significant b-galactosidase activity and the ability to grow without histidine and uracil (Fig. 6b) , indicating a robust protein-protein interaction. Next, we determined the region of utrophin responsible for the interaction with synArfGEF using two-hybrid assays with synArfGEF bait and various truncated mutants of utrophin as shown in Fig 6a. Yeast expressing synArfGEF and utrophin fragments 2691-3429, 2691-3111 and 2691-3058 exhibited detectable b-galactosidase activity, although the prototrophy for histidine and uracil was markedly disturbed in yeast expressing utrophin 2691-3111 and 2691-3058 (Fig. 6b) . The interaction was not detected when utrophin 2691-3058 was further truncated (amino acids 2810-3058, 2691-2843, or 2810-2843) or the WW motif was deleted (utrophin fragments 2843-3429, 3061-3429, and 3249-3429) (Fig. 6a) . These findings suggest that the minimal region of utrophin required for the interaction corresponds to amino acids 2691-3058.
The synArfGEF-utrophin interaction was also independently verified using pull down assays. Consistently, GST-utrophin 2691-3429, 2691-3058 and GST-dystrophin 2937-3685 were capable of efficient pull down of fulllength FLAG-synArfGEF from transfected COS-7 cell lysates, whereas neither GST-utrophin 2691-2843 nor GST alone was capable of mediating this interaction (Fig. 6c) . The synArfGEF-utrophin interaction was retained even when the salt concentration in the washing buffer was raised to 300 mM, although the interaction between GSTutrophin 2691-3058 and synArfGEF was decreased (Fig. 6c) . Furthermore, GST-utrophin 2691-3429 and GST-dystrophin 2937-3685, but not GST alone, efficiently pulled down endogenous synArfGEF from brain extracts (Fig. 6d) .
The C-terminal 73 amino acids of synArfGEF used as bait contain a proline-rich sequence and type I PDZ-binding motif. The proline-rich domain is followed by a tyrosine residue (sequence PPPPY), which forms a known motif for binding to WW domains -the PY motif (Chen and Sudol 1995; Rentschler et al. 1999) (Fig. 7a) . As the minimal region of utrophin required for robust interactions with synArfGEF contains a WW motif, we examined whether this PY motif mediated the synArfGEF-utrophin interaction. Activation of reporter genes was observed when yeast was co-transformed with utrophin 2653-3429 and synArfGEF 1122-1194, DC3, 1122-1172, or 1141-1194, all of which contained the PY motif, although the b-galactosidase activity was dramatically reduced in the yeast transformed with (Fig. 7b) . The substitution of proline and tyrosine residues in the PY motif to alanine residues (PPPPY fi PPAPA) disrupted the interaction between synArfGEF and utrophin ( Fig. 7a and b) , suggesting that the PY motif in synArfGEF is critical for this interaction.
To examine whether synArfGEF and utrophin/dystrophin co-localize at synapses, cultured hippocampal neurons were prepared from rat embryos, maintained for 22 days and immunostained with antibodies against synArfGEF and dystrophin or utrophin. Dendritic synArfGEF puncta showed extensive colocalization with dystrophin ( Fig. 8b-d) . By contrast, anti-utrophin did not immunolabel hippocampal neurons (data not shown). Furthermore, synArfGEF-immunoreactive puncta were also associated with GABA A R a1 subunit and VGAT but not with PSD-95 (Fig. 8e-m) . Taken together, these findings suggest that synArfGEF and dystrophin form a complex at inhibitory synapses of hippocampal neurons in vivo, mediated by PY-motif and WW domain interactions. Lysates from COS-7 cells transfected with pCAGGS-FLAG-synArfGEF (c) and mouse brains (d) were subjected to pull down assays with the indicated GST fusion proteins that were conjugated with glutathione-Sepharose 4B. The precipitates were washed with the lysis buffer containing 150 or 300 mM NaCl and subjected to Western blot analysis with anti-FLAG IgG (c) or anti-synArfGEF IgG (d).
Interaction of synArfGEF with S-SCAM/MAGI-2
In addition to utrophin, we also isolated several independent clones encoding the membrane-associated guanylate kinase with inverted orientation (MAGI) family, which contains six PDZ domains, two WW domains and one guanylate kinase domain and comprises of three members, MAGI-1, S-SCAM (also called MAGI-2), and MAGI-3. S-SCAM was previously shown to localize at inhibitory synapses and to act as a molecular bridge between the neurexin-neuroligin complex and the DGC via direct interactions with two adhesion molecules at inhibitory synapses, neuroligin-2 and b-dystroglycan (Sumita et al. 2007) . We therefore examined whether synArfGEF could interact with S-SCAM using pull down assays (Fig. 9a) . GST-synArfGEF 1122-1194 efficiently pulled down full-length S-SCAM from lysates of transfected COS-7 cells. We further determined which region of S-SCAM was responsible for this interaction using various truncated S-SCAM mutants as shown in Fig. 9a . GSTsynArfGEF 1122-1194 could efficiently pull down S-SCAM 295-578 containing two WW domains and the PDZ1 domain, while it could not pull down S-SCAM 1-301 or 573-1277. Although the binding efficiency was drastically reduced, S-SCAM 425-578 containing only PDZ1 domain retained the ability to bind to GST-synArfGEF 1122-1194 (Fig. 9a) , indicating that PDZ1 domain is the minimal requirement for the interaction with synArfGEF.
To examine whether synArfGEF co-localizes with S-SCAM at synapses, we performed double immunofluorescent staining of the cerebellar cortex (Fig. 9b) . In the molecular layer, both synArfGEF and S-SCAM were distributed in puncta, although S-SCAM puncta were slightly larger in size. The anti-synArfGEF IgG labeled 43% of S-SCAM puncta (n = 202), whereas the anti-S-SCAM IgG labeled 26% of synArfGEF puncta (n = 335). These findings suggest that synArfGEF partially co-localizes with S-SCAM in the cerebellar molecular layer.
Finally, we performed co-immunoprecipiation experiments from brain lysates to examine whether synArfGEF forms a proteins complex with dystrophin and S-SCAM in vivo. The anti-synArfGEF IgG, but not normal rabbit IgG, efficiently immunoprecipitated S-SCAM from the deoxycholate-solubilized P2 fraction (Fig. 9c) . Although we failed to detect dystrophin or utrophin in the immunoprecipitates (data not shown), the anti-synArfGEF IgG clearly immunoprecipitated b-dystroglycan from the deoxycholate-solubilized P2 fraction (Fig. 9c) . Taken together, these results suggest that synArfGEF is likely to be present in the DGC and associate with S-SCAM at inhibitory synapses.
Discussion
The BRAG/IQSEC family is composed of three members, IQ-ArfGEF/BRAG1/IQSEC2, GEP100/BRAG2/IQSEC1, and synArfGEF/BRAG3/IQSEC3, all of which share characteristic domain organization containing an N-terminal IQ-like motif, a central Sec7 domain and pleckstrin homology domain (Table 1 ). GEP100/BRAG2/IQSEC1, a prototypical member of this family, was shown to activate Arf6 in vitro and in vivo (Someya et al. 2001; Morishige et al. 2008) . IQ-ArfGEF/BRAG1/IQSEC2 was subsequently shown to activate Arf6 using pull down assays with GST-GGA1 (Sakagami et al. 2008) . In this study, we have shown that synArfGEF/BRAG3/IQSEC3 also functions as a GEF for Arf6 in vivo by using pull down and transferrin incorporation assays. However, we were unable to conclusively demonstrate the GEF activity of synArfGEF toward Arf1, because co-transfection of synArfGEF and Arf1 increased total Arf1 in the lysate to the same extent as GTP-Arf1 pulled down by GST-GGA1. By contrast, Hattori et al. (2007) have previously shown that KIAA1110, encoding a human homologue of synArfGEF, exhibits GEF activity toward Arf1 but not Arf6 using an Arf pull down assay with the same GST-GGA1. The reasons for this discrepancy are unknown at present. However, as KIAA1110 is a partial 770 amino acid protein corresponding to amino acids 439-1194 of rat synArfGEF, the complete structure of synArfGEF may be required for GEF activity toward Arf6.
The PSD of excitatory synapses is known to contain a diverse array of GEFs and GTPase-activating proteins (GAPs) for small GTPases: Ras-GAP (synGAP) (Chen et al. 1998) , Arf-GEFs (BRAG1, BRAG2b) (Murphy et al. 2006; Dosemeci et al. 2007; Sakagami et al. 2008) , Arf-GAPs (GIT1 and PIKE-L) (Peng et al. 2004) , Rac-GEF (Kalirin) (Penzes et al. 2000) , Rap-GEF (cAMP-GEFII/Epac2) (Peng (Pak et al. 2001) . These regulatory proteins for small GTPases are proposed to modulate synaptic transmission by regulating the formation and maintenance of dendritic spines and synapses through the actin cytoskeleton reorganization (Penzes et al. 2001; Zhang et al. 2003 Zhang et al. , 2005 Vazquez et al. 2004; Woolfrey et al. 2009 ). Among the BRAG family, IQ-ArfGEF/BRAG1/ IQSEC2 was shown to localize at the PSD of excitatory synapses and form a protein complex with NMDA-type glutamate receptors, possibly via an interaction with PSD-95 (Murphy et al. 2006; Dosemeci et al. 2007; Sakagami et al. 2008) and insulin receptor tyrosine kinase substrate of 53 kDa (IRSp53) (Sanda et al. 2009) (Table 1) . Mutations in IQSEC2 have recently been reported in patients with nonsyndromic X chromosome-linked intellectual disability (Shoubridge et al. 2010) . Interestingly, mutations in three of four separate families with non-syndromic X chromosome-linked intellectual disability lead to amino acid substitutions in the Sec7 domain and consequent reduction of the GEF activity toward Arf6, suggesting the functional significance of IQSEC2-Arf6 pathway in neuronal morphology or synaptic plasticity (Shoubridge et al. 2010) . In sharp contrast, we show that synArfGEF localizes preferentially at post-synaptic specializations of inhibitory synapses. This major finding was confirmed by several independent lines of immunohistochemical evidence. To our knowledge, the only known regulator of small GTPases found at inhibitory postsynaptic specializations is collybistin, a GEF for Cdc42, which was identified as an interacting protein for gephyrin by yeast two-hybrid screening (Kins et al. 2000) . Thus, synArfGEF is listed as the second known regulator of GTPase that shows preferential localization at post-synaptic specializations of inhibitory synapses. What are the potential roles of synArfGEF at inhibitory synapses? The Arf family comprises six structurally related members that regulate membrane trafficking and the actin cytoskeleton (D'Souza-Schorey and Chavrier 2006). Of the six Arf members, Arf6 is localized at the plasma membrane and endosomes, and regulates the endosome-plasma membrane traffic and remodeling of the actin cytoskeleton at the cell surface. At synapses, the submembrane cytoskeleton is known to regulate the number and dynamics of neurotransmitter receptors on the post-synaptic membrane, thereby modulating synaptic efficacy. At inhibitory synapses, both (Charrier et al. 2006) . In addition, gephyrin interacts with various regulatory proteins for the cytoskeleton, including polymerized tubulin (Kirsch et al. 1991) , profilin (Mammoto et al. 1998) and mammalian enabled/vasodilator stimulated phosphoprotein (Giesemann et al. 2003) . In turn, gephyrin depends on both actin and microtubules for synaptic apposition and scaffold formation (Kirsch and Betz 1995) . It is therefore possible that synArfGEF may initiate local remodeling of the synaptic submembrane actin cytoskeleton through the activation of Arf6, thereby modulating the lateral diffusion and stabilization of neurotransmitter receptors and gephyrin at inhibitory synapses. Another noteworthy finding is that synArfGEF interacts with utrophin/dystrophin and S-SCAM via a PY motif and PDZ-binding motif in the C-terminal region, respectively. The ability of synArfGEF to bind utrophin/dystrophin was verified by both yeast two-hybrid and pull down assays. Although we failed to detect dystrophin or utrophin in coimmunoprecipitation assays, b-dystroglycan and S-SCAM were immunoprecipitated from brain lysates by the antisynArfGEF IgG. Consistent with previous findings demonstrating that dystrophin and S-SCAM are localized to inhibitory synapses (Knuesel et al. 1999; Sumita et al. 2007) , immunostaining showed the colocalization of synArfGEF with dystrophin and S-SCAM. However, the antiutrophin antibody raised in this study did not result in any immunolabeling in the cultured hippocampal neurons. This is consistent with previous findings suggesting that utrophin transcripts are predominantly expressed in endothelial cells of blood vessels rather than in neurons (Knuesel et al. 2000) . Hence, it is likely that S-SCAM and dystrophin, but not utrophin, are physiological binding partners for synArfGEF. At inhibitory synapses, dystrophin forms the DGC with a-and b-dystroglycan, syntrophin, and a-and bdystrobrevin. Intriguingly, S-SCAM was shown to interact directly with two inhibitory post-synaptic components, bdystroglycan and neuroligin-2 (Sumita et al. 2007 ). Thus, the interaction of synArfGEF with dystrophin and S-SCAM enables synArfGEF to activate Arf6 in the proximity of the DGC and neuroligin-2 at inhibitory post-synaptic specializations. Mdx mice lacking a long form of dystrophin exhibit a marked reduction in the clustering of GABA A Rs containing the a2 subunit but retain gephyrin clustering in the cerebellar cortex, suggesting a dystrophin-dependent and gephyrin-independent mechanism for the clustering of selected GABA A R subtypes. In the future, it will be of particular interest to examine the possibility that synArfGEF is involved in the dystrophin-dependent clustering of GABA A Rs through Arf6-dependent actin cytoskeleton remodeling.
Finally, it should be noted that the interaction of synArfGEF with dystrophin and S-SCAM cannot account for the specific mechanism for the targeting of synArfGEF to inhibitory synapses, because dystrophin and S-SCAM are only present at a subset of inhibitory synapses and S-SCAM is present at both excitatory and inhibitory synapses (Knuesel et al. 1999; Levi et al. 2002; Sumita et al. 2007) . Therefore, additional factors are required for specific targeting of synArfGEF to inhibitory synapses.
In conclusion, we have demonstrated that synArfGEF activates Arf6 and localizes preferentially at inhibitory postsynaptic specializations, forming a protein complex with the DGC and S-SCAM using distinct binding motifs. These findings link Arf6 signaling pathways to inhibitory synapses and suggest that synArfGEF may influence dynamic processes affecting the synaptic localization of inhibitory GABA A and glycine receptors.
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